TORONTO, May 22, 2024 /CNW/ - Newtopia Inc. ("Newtopia" or the "Company") (TSXV: NEWU) (OTCQB: NEWUF), a tech-enabled whole health platform creating sustainable habits that prevent, slow, and reverse chronic disease, announced today that it will release combined financial results for the quarter ended December 31, 2023, and March 31, 2024, after market close on Thursday May 23rd, 2024. The Company will also host a conference call that day at 5:00 p.m. Eastern Time to discuss the fourth quarter 2023 and first quarter 2024 results in further detail.
To access the conference call, please dial (800) 717-1738 (U.S.) or (646) 307-1865 (International) ten minutes prior to the start time and reference Conference ID number 69589. The call will also be available via live webcast on the investor relations portion of the Company's website located at investor.newtopia.com.
If you cannot listen to the conference call at its scheduled time, there will be a replay available through June 13, 2024, which can be accessed by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (International) and entering the passcode 11156056. The webcast will also be archived on the Company's website.
About Newtopia
Newtopia is a personalized whole health platform helping people create positive lifelong habits that prevent, slow, or reverse chronic disease while reducing healthcare costs. The platform leverages genetic, social, and behavioral insights to create individualized prevention programs with a focus on metabolic disease, diabetes, mental health challenges, hypertension, weight management and musculoskeletal disorders. With a person-centered approach that combines virtual care, digital tools, connected devices and actionable data science, Newtopia delivers sustainable clinical and financial outcomes. Newtopia serves some of the largest nationwide employers and health plans and is currently listed in Canada on the Toronto Stock Exchange (TSXV: NEWU) and is quoted in the US on the OTCQB® Venture Market (OTCQB: NEWUF). To learn more, visit newtopia.com, LinkedIn or X.
| Last Trade: | C$0.01 |
| Daily Volume: | 0 |
| Market Cap: | C$1.730M |
September 24, 2024 September 17, 2024 August 08, 2024 May 23, 2024 January 29, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
